Commerce Bank Raises Holdings in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Commerce Bank increased its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 20.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 11,646 shares of the life sciences company’s stock after purchasing an additional 1,988 shares during the quarter. Commerce Bank’s holdings in Integra LifeSciences were worth $797,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP acquired a new position in Integra LifeSciences in the second quarter valued at $1,969,000. Cubist Systematic Strategies LLC boosted its holdings in Integra LifeSciences by 127.6% in the second quarter. Cubist Systematic Strategies LLC now owns 16,695 shares of the life sciences company’s stock valued at $1,139,000 after acquiring an additional 9,359 shares during the last quarter. Nordea Investment Management AB boosted its holdings in Integra LifeSciences by 98.9% in the third quarter. Nordea Investment Management AB now owns 197,640 shares of the life sciences company’s stock valued at $14,000,000 after acquiring an additional 98,287 shares during the last quarter. Campbell Newman Asset Management Inc. boosted its holdings in Integra LifeSciences by 5.5% in the third quarter. Campbell Newman Asset Management Inc. now owns 12,167 shares of the life sciences company’s stock valued at $833,000 after acquiring an additional 634 shares during the last quarter. Finally, Texas Permanent School Fund boosted its holdings in Integra LifeSciences by 1.7% in the third quarter. Texas Permanent School Fund now owns 53,807 shares of the life sciences company’s stock valued at $3,685,000 after acquiring an additional 880 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

A number of research analysts recently weighed in on IART shares. Credit Suisse Group lifted their target price on Integra LifeSciences from $84.00 to $87.00 and gave the company an “outperform” rating in a report on Wednesday, November 3rd. JMP Securities restated a “buy” rating on shares of Integra LifeSciences in a research note on Wednesday, November 3rd. Finally, JPMorgan Chase & Co. upgraded Integra LifeSciences from an “underweight” rating to a “neutral” rating and set a $75.00 price objective on the stock in a research note on Friday, December 17th. Six research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $77.22.

In related news, EVP Michael J. Mcbreen sold 3,450 shares of the business’s stock in a transaction dated Friday, November 5th. The stock was sold at an average price of $71.59, for a total value of $246,985.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Glenn Coleman sold 4,275 shares of the business’s stock in a transaction dated Tuesday, November 2nd. The shares were sold at an average price of $74.00, for a total value of $316,350.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 282,725 shares of company stock valued at $19,669,586. 4.20% of the stock is owned by corporate insiders.

Shares of NASDAQ IART opened at $68.79 on Friday. Integra LifeSciences Holdings Co. has a 1 year low of $61.85 and a 1 year high of $77.40. The firm has a market cap of $5.83 billion, a price-to-earnings ratio of 27.08, a PEG ratio of 1.53 and a beta of 1.20. The company has a debt-to-equity ratio of 0.92, a quick ratio of 2.33 and a current ratio of 3.32. The stock’s 50-day simple moving average is $66.95 and its 200-day simple moving average is $69.06.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Monday, November 1st. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.72 by $0.14. Integra LifeSciences had a return on equity of 17.33% and a net margin of 14.19%. The business had revenue of $386.86 million for the quarter, compared to analyst estimates of $384.47 million. During the same period in the previous year, the company earned $0.80 earnings per share. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, research analysts predict that Integra LifeSciences Holdings Co. will post 3.15 EPS for the current year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.

Featured Article: How to execute a trade ex-dividend strategy?

Institutional Ownership by Quarter for Integra LifeSciences (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.